[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse ACOX3

Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Peroxisome
Domain PF01756 Acyl-CoA oxidase
PF02770 Acyl-CoA dehydrogenase
Function

Oxidizes the CoA-esters of 2-methyl-branched fatty acids.

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006635 fatty acid beta-oxidation
GO:0009062 fatty acid catabolic process
GO:0016042 lipid catabolic process
GO:0016054 organic acid catabolic process
GO:0019395 fatty acid oxidation
GO:0030258 lipid modification
GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase
GO:0033540 fatty acid beta-oxidation using acyl-CoA oxidase
GO:0034440 lipid oxidation
GO:0044242 cellular lipid catabolic process
GO:0044282 small molecule catabolic process
GO:0046395 carboxylic acid catabolic process
GO:0055088 lipid homeostasis
GO:0072329 monocarboxylic acid catabolic process
Molecular Function GO:0000062 fatty-acyl-CoA binding
GO:0003995 acyl-CoA dehydrogenase activity
GO:0003997 acyl-CoA oxidase activity
GO:0009055 electron carrier activity
GO:0016402 pristanoyl-CoA oxidase activity
GO:0016627 oxidoreductase activity, acting on the CH-CH group of donors
GO:0016634 oxidoreductase activity, acting on the CH-CH group of donors, oxygen as acceptor
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050662 coenzyme binding
GO:0052890 oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor
GO:1901681 sulfur compound binding
Cellular Component GO:0005777 peroxisome
GO:0005782 peroxisomal matrix
GO:0031907 microbody lumen
GO:0042579 microbody
GO:0044438 microbody part
GO:0044439 peroxisomal part
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa04024 cAMP signaling pathway
hsa04146 Peroxisome
hsa00071 Fatty acid degradation
hsa00592 alpha-Linolenic acid metabolism
hsa01040 Biosynthesis of unsaturated fatty acids
hsa01100 Metabolic pathways
hsa01212 Fatty acid metabolism
Reactome R-HSA-389887: Beta-oxidation of pristanoyl-CoA
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-390918: Peroxisomal lipid metabolism
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACOX3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACOX3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACOX3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1290.539
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1480.903
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3310.717
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.280.479
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4930.811
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.010.997
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0170.947
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1320.899
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1350.909
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1240.921
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3910.83
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1960.0656
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACOX3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACOX3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACOX3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACOX3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACOX3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACOX3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACOX3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACOX3
Nameacyl-CoA oxidase 3, pristanoyl
Aliases acyl-Coenzyme A oxidase 3, pristanoyl; branched-chain acyl-CoA oxidase; pristanoyl-CoA oxidase; Peroxisomal ......
Chromosomal Location4p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACOX3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.